300 related articles for article (PubMed ID: 18179253)
1. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein.
Smith DP; Tew DJ; Hill AF; Bottomley SP; Masters CL; Barnham KJ; Cappai R
Biochemistry; 2008 Feb; 47(5):1425-34. PubMed ID: 18179253
[TBL] [Abstract][Full Text] [Related]
2. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
Ramakrishnan M; Jensen PH; Marsh D
Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into the interaction between alpha-synuclein and docosahexaenoic acid.
De Franceschi G; Frare E; Bubacco L; Mammi S; Fontana A; de Laureto PP
J Mol Biol; 2009 Nov; 394(1):94-107. PubMed ID: 19747490
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein selectively binds to anionic phospholipids embedded in liquid-disordered domains.
Stöckl M; Fischer P; Wanker E; Herrmann A
J Mol Biol; 2008 Feb; 375(5):1394-404. PubMed ID: 18082181
[TBL] [Abstract][Full Text] [Related]
5. Helical alpha-synuclein forms highly conductive ion channels.
Zakharov SD; Hulleman JD; Dutseva EA; Antonenko YN; Rochet JC; Cramer WA
Biochemistry; 2007 Dec; 46(50):14369-79. PubMed ID: 18031063
[TBL] [Abstract][Full Text] [Related]
6. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
[TBL] [Abstract][Full Text] [Related]
7. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
8. A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers.
Madine J; Doig AJ; Middleton DA
Biochemistry; 2006 May; 45(18):5783-92. PubMed ID: 16669622
[TBL] [Abstract][Full Text] [Related]
9. Calcium-triggered membrane interaction of the alpha-synuclein acidic tail.
Tamamizu-Kato S; Kosaraju MG; Kato H; Raussens V; Ruysschaert JM; Narayanaswami V
Biochemistry; 2006 Sep; 45(36):10947-56. PubMed ID: 16953580
[TBL] [Abstract][Full Text] [Related]
10. Secondary structural formation of alpha-synuclein amyloids as revealed by g-factor of solid-state circular dichroism.
Lin XJ; Zhang F; Xie YY; Bao WJ; He JH; Hu HY
Biopolymers; 2006 Oct; 83(3):226-32. PubMed ID: 16752390
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism of interaction between alpha-synuclein and biological membranes.
Kim YS; Laurine E; Woods W; Lee SJ
J Mol Biol; 2006 Jul; 360(2):386-97. PubMed ID: 16762368
[TBL] [Abstract][Full Text] [Related]
12. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.
Ghosh D; Sahay S; Ranjan P; Salot S; Mohite GM; Singh PK; Dwivedi S; Carvalho E; Banerjee R; Kumar A; Maji SK
Biochemistry; 2014 Oct; 53(41):6419-21. PubMed ID: 25268550
[TBL] [Abstract][Full Text] [Related]
13. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
Luk KC; Hyde EG; Trojanowski JQ; Lee VM
Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
[TBL] [Abstract][Full Text] [Related]
14. Conformational properties of the SDS-bound state of alpha-synuclein probed by limited proteolysis: unexpected rigidity of the acidic C-terminal tail.
de Laureto PP; Tosatto L; Frare E; Marin O; Uversky VN; Fontana A
Biochemistry; 2006 Sep; 45(38):11523-31. PubMed ID: 16981712
[TBL] [Abstract][Full Text] [Related]
15. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species.
Braga CA; Follmer C; Palhano FL; Khattar E; Freitas MS; Romão L; Di Giovanni S; Lashuel HA; Silva JL; Foguel D
J Mol Biol; 2011 Jan; 405(1):254-73. PubMed ID: 21050861
[TBL] [Abstract][Full Text] [Related]
16. The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro.
Ghosh D; Mondal M; Mohite GM; Singh PK; Ranjan P; Anoop A; Ghosh S; Jha NN; Kumar A; Maji SK
Biochemistry; 2013 Oct; 52(40):6925-7. PubMed ID: 24047453
[TBL] [Abstract][Full Text] [Related]
17. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
Bharathi ; Indi SS; Rao KS
Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of alpha-synuclein aggregation by homologous peptides.
Du HN; Li HT; Zhang F; Lin XJ; Shi JH; Shi YH; Ji LN; Hu J; Lin DH; Hu HY
FEBS Lett; 2006 Jun; 580(15):3657-64. PubMed ID: 16764865
[TBL] [Abstract][Full Text] [Related]
19. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation of N-terminally acetylated α-synuclein.
O'Leary EI; Jiang Z; Strub MP; Lee JC
J Biol Chem; 2018 Jul; 293(28):11195-11205. PubMed ID: 29853639
[TBL] [Abstract][Full Text] [Related]
20. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation.
Martinez Z; Zhu M; Han S; Fink AL
Biochemistry; 2007 Feb; 46(7):1868-77. PubMed ID: 17253773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
